UK markets closed
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • FTSE 250

    22,775.28
    +283.92 (+1.26%)
     
  • AIM

    1,262.60
    +9.91 (+0.79%)
     
  • GBP/EUR

    1.1495
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.3990
    +0.0098 (+0.70%)
     
  • BTC-GBP

    41,536.96
    -578.52 (-1.37%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • DOW

    34,777.76
    +229.23 (+0.66%)
     
  • CRUDE OIL

    64.82
    +0.11 (+0.17%)
     
  • GOLD FUTURES

    1,832.00
    +16.30 (+0.90%)
     
  • NIKKEI 225

    29,357.82
    +26.45 (+0.09%)
     
  • HANG SENG

    28,610.65
    -26.81 (-0.09%)
     
  • DAX

    15,399.65
    +202.91 (+1.34%)
     
  • CAC 40

    6,385.51
    +28.42 (+0.45%)
     

2021 Pipeline Analysis for Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis: Therapeutic Assessment, Unmet Needs and Impact of Drugs

Research and Markets
·3-min read

Dublin, May 04, 2021 (GLOBE NEWSWIRE) -- The "Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Advanced Hepatocellular Carcinoma with CPB liver cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Hepatocellular Carcinoma with CPB liver cirrhosis pipeline landscape is provided which includes the disease overview and Advanced Hepatocellular Carcinoma with CPB liver cirrhosis treatment guidelines.

The assessment part of the report embraces, in depth Advanced Hepatocellular Carcinoma with CPB liver cirrhosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Hepatocellular Carcinoma with CPB liver cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

There are approx. 3+ key companies which are developing the therapies for Advanced Hepatocellular Carcinoma with CPB liver cirrhosis. The companies which have their Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drug candidates in the most advanced stage, i.e. phase II include, Can-Fite Biophama.

The report covers around 3+ products under different phases of clinical development:

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Key Report Insights

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Key Report Assessments

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drugs?

  • How many Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Hepatocellular Carcinoma with CPB liver cirrhosis?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Hepatocellular Carcinoma with CPB liver cirrhosis therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Advanced Hepatocellular Carcinoma with CPB liver cirrhosis and their status?

  • What are the key designations that have been granted to the emerging drugs?


Key Topics Covered:

  • Executive Summary

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis: Overview

  • Pipeline Therapeutics

  • Therapeutic Assessment

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Analytical Perspective

  • In-depth Commercial Assessment

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Collaboration Deals

  • Mid Stage Products (Phase II)

  • Namodenoson: Can-Fite Biopharma

  • Early Stage Products (Phase I)

  • Inactive Products

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Key Companies

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Key Products

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Unmet Needs

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Market Drivers and Barriers

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Future Perspectives and Conclusion

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Analyst Views

  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Key Companies


For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/t8tkxp

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900